Literature DB >> 15144868

Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone.

Sheila M Fleming1, Chunni Zhu, Pierre-Olivier Fernagut, Arpesh Mehta, Cheryl D DiCarlo, Ronald L Seaman, Marie-Françoise Chesselet.   

Abstract

Mitochondrial toxins such as the complex 1 inhibitor rotenone are widely used as pesticides and may be present in military environments. Administration of rotenone can induce biochemical and histological alterations similar to those of Parkinson's disease in rats. However, only a subset of animals show these effects and it is unclear whether more subtle alterations are caused by chronic administration of rotenone in those animals that appear resistant to its toxic effects on dopaminergic nerve terminals. To address this question, vehicle or rotenone (2.0, 2.5, or 3.5 mg/kg/day) was administered intravenously or subcutaneously for 21 days to adult rats, and rotenone effects on survival, motor behavior, and striatal tyrosine hydroxylase immunoreactivity (TH-IR) were examined. Both intravenous and subcutaneous rotenone induced a dose-dependent decrease in survival rates. Surviving animals showed a decrease in spontaneous rearing. Locomotor activity and movement initiation time were also altered in some of the experimental groups. Confirming previous results, TH-IR in the striatum was markedly decreased in rats that fell ill early in the study and in a few of the surviving rats with high rotenone doses. However, none of the surviving rats receiving 2.0 mg/kg/day showed TH-IR loss reminiscent of Parkinson's disease, and loss of striatal TH-IR across doses was not correlated with motor behavior in individual rats. Thus, chronic administration of low doses of rotenone induces motor anomalies even in animals that do not develop histological signs of Parkinson's disease, indicating a pervasive neurological effect of moderate mitochondrial dysfunction in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15144868     DOI: 10.1016/j.expneurol.2004.01.023

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  64 in total

1.  Exercise Effects on Early Vocal Ultrasonic Communication Dysfunction in a PINK1 Knockout Model of Parkinson's Disease.

Authors:  Cynthia A Kelm-Nelson; Katie M Yang; Michelle R Ciucci
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

2.  Dopaminergic neuronal injury in the adult rat brain following neonatal exposure to lipopolysaccharide and the silent neurotoxicity.

Authors:  Lir-Wan Fan; Lu-Tai Tien; Baoying Zheng; Yi Pang; Rick C S Lin; Kimberly L Simpson; Tangeng Ma; Philip G Rhodes; Zhengwei Cai
Journal:  Brain Behav Immun       Date:  2010-09-27       Impact factor: 7.217

3.  Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.

Authors:  R Lee Mosley; Eric J Benner; Irena Kadiu; Mark Thomas; Michael D Boska; Khader Hasan; Chad Laurie; Howard E Gendelman
Journal:  Clin Neurosci Res       Date:  2006-12-06

4.  Neuroprotective effects of metallothionein against rotenone-induced myenteric neurodegeneration in parkinsonian mice.

Authors:  Shinki Murakami; Ikuko Miyazaki; Norio Sogawa; Ko Miyoshi; Masato Asanuma
Journal:  Neurotox Res       Date:  2014-06-13       Impact factor: 3.911

5.  Rotenone exerts developmental neurotoxicity in a human brain spheroid model.

Authors:  David Pamies; Katharina Block; Pierre Lau; Laura Gribaldo; Carlos A Pardo; Paula Barreras; Lena Smirnova; Daphne Wiersma; Liang Zhao; Georgina Harris; Thomas Hartung; Helena T Hogberg
Journal:  Toxicol Appl Pharmacol       Date:  2018-02-08       Impact factor: 4.219

6.  Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways.

Authors:  Shih-Ling Hsuan; Heather M Klintworth; Zhengui Xia
Journal:  J Neurosci       Date:  2006-04-26       Impact factor: 6.167

Review 7.  Neurobehavioural Changes in a Hemiparkinsonian Rat Model Induced by Rotenone.

Authors:  Sukala Puthuparambil Maniyath; Narayanan Solaiappan; Muthusamy Rathinasamy
Journal:  J Clin Diagn Res       Date:  2017-03-01

8.  Neonatal systemic exposure to lipopolysaccharide enhances susceptibility of nigrostriatal dopaminergic neurons to rotenone neurotoxicity in later life.

Authors:  Zhengwei Cai; Lir-Wan Fan; Asuka Kaizaki; Lu-Tai Tien; Tangeng Ma; Yi Pang; Shuying Lin; Rick C S Lin; Kimberly L Simpson
Journal:  Dev Neurosci       Date:  2013-02-22       Impact factor: 2.984

Review 9.  Animal models of Parkinson's disease progression.

Authors:  Gloria E Meredith; Patricia K Sonsalla; Marie-Francoise Chesselet
Journal:  Acta Neuropathol       Date:  2008-02-14       Impact factor: 17.088

10.  A highly reproducible rotenone model of Parkinson's disease.

Authors:  Jason R Cannon; Victor Tapias; Hye Mee Na; Anthony S Honick; Robert E Drolet; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2009-05       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.